Regeneron $REGN Q2 2023

Regeneron REGN 0.00%↑ , the therapeutic antibodies company, presented Q2 2023 results, and the stock is up +4% in pre-market. Some highlights include data from Dupilumab in COPD and some Itepekimab data in COPD for former smokers.

Anti-IL4RA and anti-IL33 antibodies are both monoclonal antibodies that are being developed for the treatment of allergic diseases. They work by blocking the action of their respective targets, which are IL-4RA and IL-33. IL-4RA is a receptor for IL-4, a cytokine that plays a key role in the development of allergic inflammation. IL-33 is a pro-inflammatory cytokine that is produced by cells in the skin and airways.

Below we analyse the pros and cons of both antibodies, and the strategy of both companies, REGN 0.00%↑ Regeneron and Sanofi going forward…